NeurAxis, Inc. (NRXS)Healthcare | Biotechnology | Carmel, United States | NYSE American
6.00 USD
-0.02
(-0.332%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 6.00 |
Hot Take ↕ | Aug. 22, 2026, 4:50 a.m. EDT
The investment case here is defined by a stark disconnect between the company's explosive top-line growth and its deteriorating share price. While revenues surged 80% year-over-year and the company secured new payer coverage, the stock has fallen nearly 60% over the last two years, with the trailing twelve months showing a massive decline. This suggests the market is pricing in a severe future reality—likely the inability to convert these sales into profitability given the negative operating margins and free cash flow burn. The balance sheet is currently fragile, with negative free cash flow and a high debt-to-equity ratio, making the path to a sustainable dividend impossible. While the recent earnings beat and guidance upgrade provide a temporary catalyst, the fundamental reality of burning cash with no earnings remains a heavy anchor. The options market is betting on a recovery, but until the company demonstrates a clear path to profitability or a massive cash infusion, the long-term outlook remains deeply bearish. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.039616 |
| AutoETS | 0.057006 |
| AutoARIMA | 0.057231 |
| MSTL | 0.059008 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.894 |
| Excess Kurtosis | -0.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.148 |
| Revenue per Share | 0.488 |
| Market Cap | 75,346,592 |
| Forward P/E | -22.22 |
| Beta | 1.48 |
| Profit Margins | -144.44% |
| Website | https://neuraxis.com |
As of Aug. 22, 2026, 4:50 a.m. EDT: Speculators are positioning for a modest rebound rather than a crash. Call open interest is concentrated significantly out-of-the-money at the $10 strike, suggesting bets on a substantial upside move to double the current price. Conversely, put activity is negligible and entirely out-of-the-money, indicating a lack of hedging against a further decline. Implied volatility is elevated on near-term puts relative to calls, reflecting fear of a drop, yet the actual positioning leans bullish.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2889733 |
| Address1 | 11,611 North Meridian St |
| Address2 | Suite 330 |
| All Time High | 9.33 |
| All Time Low | 1.33 |
| Ask | 6.0 |
| Ask Size | 1,100 |
| Average Daily Volume10 Day | 70,760 |
| Average Daily Volume3 Month | 95,324 |
| Average Volume | 95,324 |
| Average Volume10Days | 70,760 |
| Beta | 1.475 |
| Bid | 5.97 |
| Bid Size | 200 |
| Book Value | 0.54 |
| City | Carmel |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.0 |
| Current Ratio | 3.04 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 6.105 |
| Day Low | 5.9493 |
| Debt To Equity | 4.148 |
| Display Name | NeurAxis |
| Ebitda | -7,609,116 |
| Ebitda Margins | -1.43133 |
| Enterprise To Ebitda | -8.846 |
| Enterprise To Revenue | 12.661 |
| Enterprise Value | 67,307,520 |
| Eps Current Year | -0.76 |
| Eps Forward | -0.27 |
| Eps Trailing Twelve Months | -0.76 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.723 |
| Fifty Day Average Change | -0.72300005 |
| Fifty Day Average Change Percent | -0.107541285 |
| Fifty Two Week Change Percent | 128.89734 |
| Fifty Two Week High | 9.33 |
| Fifty Two Week High Change | -3.33 |
| Fifty Two Week High Change Percent | -0.35691318 |
| Fifty Two Week Low | 2.21 |
| Fifty Two Week Low Change | 3.79 |
| Fifty Two Week Low Change Percent | 1.7149321 |
| Fifty Two Week Range | 2.21 - 9.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,691,587,800,000 |
| Float Shares | 8,447,609 |
| Forward Eps | -0.27 |
| Forward P E | -22.222221 |
| Free Cashflow | -3,154,924 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 24 |
| Fullday Change | -0.02 |
| Fullday Change Percent | -0.332226 |
| Fullday Price | 6.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.85558 |
| Gross Profits | 4,548,382 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20628999 |
| Held Percent Institutions | 0.28437 |
| Implied Shares Outstanding | 12,557,765 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana. |
| Long Name | NeurAxis, Inc. |
| Market | us_market |
| Market Cap | 75,346,592 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1789827517 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -8,453,122 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 75,597,745 |
| Number Of Analyst Opinions | 2 |
| Open | 6.06 |
| Operating Cashflow | -5,621,003 |
| Operating Margins | -1.10163 |
| Payout Ratio | 0.0 |
| Phone | 812 689 0791 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.0 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 6.02 |
| Price Eps Current Year | -7.894737 |
| Price Hint | 2 |
| Price To Book | 11.111111 |
| Price To Sales Trailing12 Months | 14.173233 |
| Profit Margins | -1.44441 |
| Quick Ratio | 2.828 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -0.332226 |
| Regular Market Day High | 6.105 |
| Regular Market Day Low | 5.9493 |
| Regular Market Day Range | 5.9493 - 6.105 |
| Regular Market Open | 6.06 |
| Regular Market Previous Close | 6.02 |
| Regular Market Price | 6.0 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 40,207 |
| Return On Assets | -0.5621 |
| Return On Equity | -1.3975999 |
| Revenue Growth | 1.157 |
| Revenue Per Share | 0.488 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,557,765 |
| Shares Percent Shares Out | 0.0327 |
| Shares Short | 410,751 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 471,181 |
| Short Name | Neuraxis, Inc. |
| Short Percent Of Float | 0.0418 |
| Short Ratio | 4.31 |
| Source Interval | 15 |
| State | IN |
| Symbol | NRXS |
| Target High Price | 13.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 8,322,258 |
| Total Cash Per Share | 0.663 |
| Total Debt | 279,392 |
| Total Revenue | 5,316,119 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.76 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.84435 |
| Two Hundred Day Average Change | 0.15565014 |
| Two Hundred Day Average Change Percent | 0.026632585 |
| Type Disp | Equity |
| Volume | 40,207 |
| Website | https://neuraxis.com |
| Zip | 46,032 |